RE:RE:RE:RE:Uplisting to NASDAQMUGMODs wrote: I will be keeping my shares on the venture and I will not be buying on the US exchange. It will all be tied together so it really shouldn't make a difference. Some might want the US dollar exposure though.
That brings up another couple points ...
I know they initially wanted to go to the NASDAQ but didn't Dan make it sound like it could be a different american exchange once they finally decide to go? Sounded like he was open to other US exchanges during BioPub ... OR ... did I misundertand the discussion ?
Also, do we move from the venture and go to the TSX before going to an American Exchange ?
My recollection too, Mugmods. At the last AGM, the Board also made mention of another senior NA stock Exchange. I am assuming that this is the NYSE. Little to be gained from the TSX: re: Canadian limitations regarding the recognition of emerging biotech stock value.
Let's hope that when the the corporation presents its share consolidation resolution to shareholders at the next AGM, it chooses a higher maximum ratio than it has in the past (10:1). At the current share price, the consolidated figure would be less than the $4USD that NASDAQ (and NYSE) normally require for a new listing (although special provisions/exemptions might apply for a small cap). It would also be less than the $5USD threshold that many investment firms would like to see before investing. A higher maximum ratio, such as 20:1, would give the company the flexibilty/cushion that it needs, optics of this increased value nothwithstanding. Let's see what happens. I am still lookng for $7-$10 post split. Or have I missed something here?
My recollection too, Mugmods. At the last AGM, the Board also made mention of another senior NA stock Exchange. I am assuming that this is the NYSE. Little to be gained from the TSX: re: Canadian limitations regarding the recognition of emerging biotech stocks value.
Let's hope that when the the corporation presents its share consolidation resolution to shareholders at the next AGM, it chooses a higher maximum ratio than it has in the past (10:1). At the current share price, the consolidated figure would be less than the $4USD that NASDAQ (and NYSE) normally require for a new listing (although special provisions/exemptions might apply for a small cap). It would also be less than the $5USD threshold that many investment firms would like to see before investing. A higher maximum ratio, such as 20:1, would give the company the flexibilty/cushion that it needs, optics of this increased value nothwithstanding. Let's see what happens. I am still lookng for $7-$10 post split.